Moreover, the potential use of abatacept—a fusion protein consisting of the extracellular domain of CTLA-4 and the Fc portion of Ig-G (CTLA4-Ig)—on MS patients has been evaluated [77,78,79]. This evidence concerns the gene CTLA4 and myeloid sarcoma.